Last edition
News about "AMBELVIST"
Bayer Secures US FDA Approval for Ambelvist, a Low-Dose MRI Contrast Agent
Bayer’s Ambelvist (gadoquatrane) has received US FDA approval for contrast-enhanced MRI in adults and children, offering effective lesion visualization while reducing gadolinium exposure through a low-dose formulation.
Ambelvist | 16/06/2026 | By News Bureau
US FDA Approves Bayer's AMBELVIST for Contrast-Enhanced MRI
Bayer’s AMBELVIST (gadoquatrane) has received US FDA approval for contrast-enhanced MRI to detect and visualise lesions with abnormal vascularity in the Central Nervous System (CNS) and other body regions. The approval expands advanced imaging options with a next-generation gadolinium-based contrast agent for improved diagnostic evaluation.
AMBELVIST | 15/06/2026 | By News Bureau | 116
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy